US 11,951,107 B2 · Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases

Abstract

Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.

Claims13

Dependent claims

The pharmaceutical composition, for treating or ameliorating bradycardia or cardiovascular disease with active pharmaceutical ingredients, comprising:

(i) theophylline or aminophylline 3.2-28.8 mg/dose, a subtherapeutically effective amount;
(ii) nifedipine 0.16-38.4 mg/dose;
(iii) betahistine 0.4-120 mg/dose;
(iv) levalbuterol or albuterol 0.03-9 mg/dose;
wherein theophylline is deuterium-enriched no less than 50%.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/059,924Filed 29 Nov 2022 · continuation

Priority

9 May 2017

Published

US 2023/0107723 A16 Apr 2023

Granted

9 Apr 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/522
Purines, e.g. adenine: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
A61K 31/4402
Non condensed pyridines; Hydrogenated derivatives thereof: only substituted in position 2, e.g. pheniramine, bisacodyl
A61K 31/4422
Non condensed pyridines; Hydrogenated derivatives thereof: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine

Family

Application62/503,902Us provisional application · filed 9 May 2017

Application62/652,812Us provisional application · filed 4 Apr 2018

Application15/973,132Parent of this continuation-in-part · filed 7 May 2018

Application16/178,257Parent of this continuation · filed 1 Nov 2018

US 2023/0107723 A1Pre-grant publication · published 6 Apr 2023

US 11,510,924 B2Parent of this continuation

US 11,266,651 B2Parent of this continuation-in-part

Application16/178,257Parent of this continuation-in-part

US 2018/0325907 A1Published application

US 2019/0070184 A1Published application

US 11,951,107 B2This patent

From the US filing history. Foreign family members aren’t listed.

Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases

Life of this patent

Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases

Life of this patent

Abstract

Claims13